Free tool
Drug Trial Radar: Oncology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
350
Not yet recruiting, industry sponsors, Oncology, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting1,443
- Completed4,611
350 trials
Showing 1 to 25, recently updated first.
- A First-in-human, Dose Escalation, and Expansion Study of BNT3211 for Participants With Advanced Solid TumorsNot yet recruiting
BioNTech SEIndustry
NCT07951359 · 345 participants (planned) · Start Nov 2026 · Primary completion Oct 2029
Drug: BNT3211 · For: Advanced Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT07950332 · 200 participants (planned) · Start Dec 2026 · Primary completion Dec 1, 2028
Drug: HRS-7172 tablet; HRS-7172; SHR-4610 ; chemotherapy and 1 more · For: Lung Cancer
Sites: Beijing, China; Hangzhou, China
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07951762 · 368 participants (planned) · Start Dec 30, 2026 · Primary completion Dec 30, 2028
Drug: SYS6043+PD-1/VEGF bispecific antibody; SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy. and 1 more · For: Advanced Solid Tumor
Shenzhen Fosun Kairos Biotechnology Co., Ltd.Industry
NCT07765524 · 32 participants (planned) · Start Dec 2026 · Primary completion Mar 2028
Drug: FKC289 infusion · For: Primary Light Chain (AL) Amyloidosis
Sites: Guangzhou, China; Nanning, China; Zhengzhou, China · 11 sites in all
Antev Ltd.Industry
NCT07457164 · 40 participants (planned) · Start Jan 2027 · Primary completion Sep 2027
Drug: Teverelix DP 180 mg · For: Advanced Prostate Cancer; GnRH Antagonist
- A Phase II Clinical Study Evaluating the Efficacy and Safety of SXRN Injection in Patients With Cancer CachexiaNot yet recruiting
Jiangsu Guiqiong Pharmaceutical Co., Ltd.Industry
NCT07890324 · 96 participants (planned) · Start Dec 2026 · Primary completion Aug 2027
Drug: SXRN Injection; SXRN Injection and 1 more · For: Cachexia-Anorexia Syndrome; Cachexia; Cancer
Sites: Beijing, China
- Phase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebimetinib in Participants With Advanced or Metastatic NSCLC.Not yet recruiting
Immuneering CorporationIndustry
NCT07946848 · 100 participants (planned) · Start Dec 2026 · Primary completion May 2029
Drug: Atebimetinib; Cemiplimab and 2 more · For: NSCLC (Advanced Non-small Cell Lung Cancer); Non-Squamous Non Small Cell Lung Cancer; Metastatic Non-Small Lung Cell Cancer and 2 more
Sites: Fairfax, Virginia
- A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumoursPivotal-lookingNot yet recruiting
GlaxoSmithKlineGSK (GSK)
NCT07947134 · 155 participants (planned) · Start Nov 25, 2026 · Primary completion Nov 16, 2029
Drug: GSK5864399 · For: Solid Tumours
- A Phase I/II Study to Learn About the Safety and Effects of a New Medicine Called IPN60350 Alone or in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Solid TumorsPivotal-lookingNot yet recruiting
IpsenIndustry
NCT07944144 · 205 participants (planned) · Start Dec 1, 2026 · Primary completion Jun 28, 2030
Drug: IPN60350 · For: Neoplasms; Neoplasm Metastasis; Neoplastic Processes and 1 more
- Ph 1/2 Study to Evaluate Safety & Tolerability of FMC-242 Alone and in Combination in Adults With Advanced Solid TumorsNot yet recruiting
Frontier Medicines CorporationIndustry
NCT07944092 · 282 participants (planned) · Start Dec 2026 · Primary completion Jan 2029
Drug: FMC-242; Trastuzumab (or biosimilar) and 3 more · For: Locally Advanced Solid Tumor
- A First-in-human (FIH), Open-label, and Multi-center Study of CS5006 in Participants With Advanced Solid TumorsNot yet recruiting
CStone PharmaceuticalsIndustry
NCT07938814 · 310 participants (planned) · Start Dec 2026 · Primary completion Jul 2029
Drug: CS5006 · For: Advanced Solid Tumors
Sites: North Ryde, Australia; Randwick, Australia; Clayton, Australia · 4 sites in all
- Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of ResponseNot yet recruiting
NanOlogy, LLC (doing business as Intryx Therapeutics, LLC)Industry
NCT07767110 · 20 participants (planned) · Start Dec 2026 · Primary completion Dec 2029
Drug: LSAM-Cisplatin · For: Diffuse Midline Glioma (DMG); Diffuse Intrinsic Pontine Glioma (DIPG); Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
- A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLCPivotal-lookingNot yet recruiting
AstraZenecaAstraZeneca (AZN)
NCT07941609 · 250 participants (planned) · Start Nov 30, 2026 · Primary completion Dec 16, 2028
Drug: Dato-DXd; Durvalumab and 1 more · For: Non-small Cell Lung Cancer (NSCLC)
Sites: Irvine, California; Oakland, California; Golden, Colorado · 87 sites in all
- 177Lu-ACT319 in FAP Expressing Solid TumorsNot yet recruiting
Actithera INC.Industry
NCT07941362 · 182 participants (planned) · Start Oct 25, 2026 · Primary completion Jul 31, 2029
Drug: 177Lu-ACT319; 177Lu-ACT319 and 6 more · For: FAP-expressing Solid Tumors; Pancreatic Ductal Adenocarcinoma (PDAC); Biliary Tract Carcinoma (BTC)
BiogenBiogen (BIIB)
NCT07939802 · 75 participants (planned) · Start Nov 19, 2026 · Primary completion Sep 19, 2028
Drug: Felzartamab; Placebo · For: Generalized Myasthenia Gravis
- A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesNot yet recruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07939815 · 171 participants (planned) · Start Nov 30, 2026 · Primary completion Dec 29, 2029
Drug: BMS-986548; Cetuximab · For: Advanced Solid Malignancies
Sites: San Antonio, Texas; West Valley City, Utah; Vancouver, Canada · 4 sites in all
Chengdu Suncadia Medicine Co., Ltd.Industry
NCT07940439 · 126 participants (planned) · Start Nov 2026 · Primary completion Dec 2030
Drug: HRS-9308 Tablet · For: Solid Tumor
Sites: Shanghai, China
- S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c MutationNot yet recruiting
ServierIndustry
NCT07722312 · 80 participants (planned) · Start Feb 1, 2027 · Primary completion Aug 11, 2029
Drug: S243249 600mg; S243249 400mg and 2 more · For: Relapsed or Refractory Acute Leukemia; Relapsed or Refractory Acute Myeloid Leukemia
- A Study of TBS-2025 Monotherapy in Participants With r/r NPM1mut AMLNot yet recruiting
TuHURA Biosciences, Inc.Industry
NCT07939971 · 55 participants (planned) · Start Dec 2026 · Primary completion Dec 2028
Drug: TBS-2025 · For: Acute Myeloid Leukemia
- KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast CancerNot yet recruiting
Beijing Konruns Pharmaceutical Co., Ltd.Industry
NCT07937605 · 168 participants (planned) · Start Nov 2026 · Primary completion Nov 2029
Drug: KC1086; Fulvestrant and 3 more · For: HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
- A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast CancerPivotal-lookingNot yet recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07935317 · 120 participants (planned) · Start Dec 2026 · Primary completion Dec 2027
Drug: Abemaciclib; Tersolisib and 3 more · For: Breast Neoplasms
Sites: Los Alamitos, California; Lakewood, Colorado; Atlanta, Georgia · 9 sites in all
- A Multicenter Study Evaluating the Efficacy and Safety of Nivolumab and Ipilimumab in Combination With NP-101 Versus Placebo in Refractory Advanced and Metastatic Gastroenteropancreatic Neuroendocrine Carcinomas (GEP-NECs)Pivotal-lookingNot yet recruiting
Novatek PharmaceuticalsIndustry
NCT07935928 · 381 participants (planned) · Start Jan 2027 · Primary completion Dec 2029
Drug: NP-101; Ipi/Nivo · For: Gastroenteropancreatic Neuroendocrine Tumors
- Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid TumorsNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07933419 · 558 participants (planned) · Start Nov 15, 2026 · Primary completion Nov 15, 2027
Drug: QLS5133; Lenvatinib mesylate; QLS5133; QL2107; Lenvatinib mesylate and 4 more · For: Clear Cell Renal Cell Carcinoma; Ovarian Cancer; Other Advanced Solid Tumors
Sites: Jinan, China
- A Modular, Phase I/II Study to Evaluate CT204V-CD19 x CD20 in Participants With Relapsed or Refractory B-Cell Malignancies.Not yet recruiting
AstraZenecaAstraZeneca (AZN)
NCT07932496 · 160 participants (planned) · Start Nov 9, 2026 · Primary completion Oct 15, 2029
Drug: CT204V-CD19 × CD20 · For: Relapsed or Refractory B-Cell Malignancies
- A Clinical Study of MHB034C for Injection in Participants With Advanced Solid TumorsNot yet recruiting
Minghui Pharmaceutical (Shanghai) LTDIndustry
NCT07928570 · 400 participants (planned) · Start Dec 20, 2026 · Primary completion Jun 15, 2028
Drug: MHB034C for Injection · For: Advanced Malignant Solid Tumor
Sites: Shanghai, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.